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Hsin-Yi Huang1, Hui-Fen Chang1, Ming-Jen Tsai2, Jhih-Si Chen1 and Mei-Jen Wang1*Abstract
Background: The pathogenesis of several neurodegenerative diseases often involves the microglial activation and
associated inflammatory processes. Activated microglia release pro-inflammatory factors that may be neurotoxic.
6-Mercaptopurine (6-MP) is a well-established immunosuppressive drug. Common understanding of their
immunosuppressive properties is largely limited to peripheral immune cells. However, the effect of 6-MP in the
central nervous system, especially in microglia in the context of neuroinflammation is, as yet, unclear. Tumor
necrosis factor-α (TNF-α) is a key cytokine of the immune system that initiates and promotes neuroinflammation.
The present study aimed to investigate the effect of 6-MP on TNF-α production by microglia to discern the
molecular mechanisms of this modulation.
Methods: Lipopolysaccharide (LPS) was used to induce an inflammatory response in cultured primary microglia or
murine BV-2 microglial cells. Released TNF-α was measured by enzyme-linked immunosorbent assay (ELISA). Gene
expression was determined by real-time reverse transcription polymerase chain reaction (RT-PCR). Signaling
molecules were analyzed by western blotting, and activation of NF-κB was measured by ELISA-based DNA binding
analysis and luciferase reporter assay. Chromatin immunoprecipitation (ChIP) analysis was performed to examine
NF-κB p65 and coactivator p300 enrichments and histone modifications at the endogenous TNF-α promoter.
Results: Treatment of LPS-activated microglia with 6-MP significantly attenuated TNF-α production. In 6-MP
pretreated microglia, LPS-induced MAPK signaling, IκB-α degradation, NF-κB p65 nuclear translocation, and in vitro
p65 DNA binding activity were not impaired. However, 6-MP suppressed transactivation activity of NF-κB and TNF-α
promoter by inhibiting phosphorylation and acetylation of p65 on Ser276 and Lys310, respectively. ChIP analyses
revealed that 6-MP dampened LPS-induced histone H3 acetylation of chromatin surrounding the TNF-α promoter,
ultimately leading to a decrease in p65/coactivator-mediated transcription of TNF-α gene. Furthermore, 6-MP
enhanced orphan nuclear receptor Nur77 expression. Using RNA interference approach, we further demonstrated
that Nur77 upregulation contribute to 6-MP-mediated inhibitory effect on TNF-α production. Additionally, 6-MP also
impeded TNF-α mRNA translation through prevention of LPS-activated PI3K/Akt/mTOR signaling cascades.
Conclusions: These results suggest that 6-MP might have a therapeutic potential in neuroinflammation-related
neurodegenerative disorders through downregulation of microglia-mediated inflammatory processes.
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Brain inflammation is a typical feature of neurodegener-
ative diseases and acute forms of brain injury. Numerous
in vivo clinical imaging and neuropathology studies sug-
gest that activated microglia, the resident immunocom-
petent and phagocytic cells in the central nervous
system (CNS), play a critical role in the pathogenesis of
neurodegenerative disorders, including Alzheimer’s dis-
ease (AD), Parkinson’s disease (PD), and multiple scler-
osis [1–3]. Under physiological conditions, microglia are
involved in immune surveillance and host defense
against infectious agents. However, microglia readily be-
come activated in response to neuronal injury or im-
munological challenges. Although microglial activation
is an indispensable defense mechanism against patho-
gens, uncontrolled and overactivated microglia can trig-
ger neurotoxicity. Release of pro-inflammatory and
cytotoxic factors, such as interleukin-1β, tumor necrosis
factor-α (TNF-α), nitric oxide (NO), and reactive oxygen
species (ROS) are believed to contribute to the neuro-
toxic effects caused by activated microglia [3]. Therefore,
control of inflammation in the brain, involving a host of
cytokines induced by microglia, might be important for
regulation of numerous pathological processes of these
diseases.
TNF-α is a pro-inflammatory cytokine that is upregu-
lated in the brain in response to various insults or injury.
TNF-α is released predominantly by activated microglia
and may contribute to primary or secondary tissue in-
jury [4, 5]. Within the brain, inflammatory processes
might be modulated by TNF-α through further activa-
tion of microglia and astrocytes [6]. TNF-α is known to
induce changes in mitochondrial ultrastructure and
function, and it also induces ROS and NO generation
thus further promoting the inflammatory response and
exacerbating the neuronal damage [7, 8]. In addition,
TNF-α can directly induce neuronal death by binding to
TNF receptor 1 to trigger intracellular death-related sig-
naling pathways [9]. TNF-α has been implicated as an
important factor for the onset and perpetuation of neu-
rodegenerative diseases, since increased levels of this
cytokine are present in the affected areas in many neuro-
degenerative diseases [10–12]. Several lines of evidence
support the concept that excess TNF-α plays a central
role in AD [10, 13]. Application of a biologic TNF-α in-
hibitor significantly improves symptoms of AD patients
[14]. Furthermore, the cerebrospinal fluid and postmor-
tem brains of PD patients display elevated levels of
TNF-α and its receptors [11]. Using engineered
dominant-negative TNF variants and the decoy TNF re-
ceptor to block soluble TNF signaling demonstrating
that TNF-dependent mechanisms are required for loss
of dopaminergic neurons in models of PD [15]. In amyo-
trophic lateral sclerosis (ALS), both TNF-α and solubleTNF receptor levels are raised in serum of patients [12].
Administration of a TNF-α antagonist has been shown
to extend lifespan and slow motor dysfunction in a
mouse model of ALS [16]. Therefore, TNF-α is a key
cytokine of the immune system that initiates and pro-
motes neuroinflammation, which under uncontrolled
conditions may lead to the development of neurodegen-
erative diseases.
6-Mercaptopurine (6-MP) belongs to the thiopurines,
a group of substances structurally related to endoge-
neous purine bases like adenine, guanine, and hypoxan-
thine. 6-MP and its long-lived prodrug, azathioprine, are
among the oldest pharmacological immunosuppressive
agents in use today. 6-MP has been used for the treat-
ment of acute childhood leukemia and chronic myelo-
cytic leukemia, inflammatory bowel disease, systemic
lupus erythematosus, inflammatory myopathies, and
rheumatoid arthritis [17, 18]. It has also been used for
the prevention of acute rejection in organ transplant pa-
tients [17]. 6-MP is converted to 6-thioguanine nucleo-
tides that act as purine analogs and incorporated into
newly synthesized DNA, which has long been considered
to be the proposed therapeutic mechanism [19]. More
work now has expanded the function of this drug by
demonstrating that 6-MP can target biological activities
outside of the purine biosynthesis pathway including
regulation of Bcl-2/Bax ratio [20], Rac1-mediated signal-
ing [21–23], and transcriptional activity of orphan nu-
clear receptor NR4A family members [24, 25].
Moreover, 6-MP inhibits atherosclerosis in a mouse
model through decreasing lesion monocyte chemo-
attractant chemokine-1 (MCP-1) levels and reducing
macrophage content [26]. Recently, Chang et al. [27]
demonstrated that 6-MP exerts a neuroprotective effect
on permanent focal cerebral occlusion in rats. However,
little is known about the effects of 6-MP in the CNS, espe-
cially in microglia in the context of neuroinflammation. In
the current study, we investigated whether 6-MP downre-
gulates microglial inflammatory responses through de-
creasing microglial TNF-α production and elucidated the
possible mechanisms of this modulation.
Methods
Materials
Lipopolysaccharide (LPS) from Escherichia coli serotype
O111:B4 and rapamycin were obtained from Calbiochem
(San Diego, CA). 6-Mercaptopurine was from Sigma-
Aldrich (St. Louis, MO). Cell culture ingredients were
purchased from Invitrogen (Carlsbad, CA). Polyclonal
rabbit anti-acetyl histone H3 (Ac-H3) was from Upstate
Biotechnology (Lake Placid, NY). Monoclonal rabbit
anti-Nur77, polyclonal rabbit anti-NOR-1, polyclonal
rabbit anti-acetyl p65 (Lys310), and polyclonal rabbit
anti-phospho-p65 (Ser276) were obtained from Abcam
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polyclonal rabbit anti-p300 was purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). All other anti-
bodies were from Cell Signaling Technology (Beverly,
MA). All other reagents were from Sigma-Aldrich (St.
Louis, MO).
Microglial cultures
Murine BV-2 microglial cells were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) supple-
mented with 10 % fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 μg/ml streptomycin at 37 °C in a hu-
midified incubator under 5 % CO2. Confluent cultures
were trypsanized. Cells were plated into 24-wells plate at
a density of 1 × 105 cells per well and then incubated for
24 h before treatment. Primary microglia were prepared
from ventral mesencephalon of 1-day-old Sprague-
Dawley rats as previously described [28]. Briefly, ventral
mesencephalic tissues, devoid of meninges and blood
vessels, were dissociated by a mild mechanical tritur-
ation. The isolated cells (5 × 107) were seeded in 150-
cm2 culture flasks in DMEM containing 10 % FBS,
100 U/ml penicillin, and 100 μg/ml streptomycin. The
cells were maintained at 37 °C in a humidified atmos-
phere of 5 % CO2 and 95 % air. The medium were chan-
ged 4 days later. Upon reaching confluence (12–
14 days), microglia were separated from astrocytes by
shaking the flasks for 2 h at 180 rpm. Detached cells
were plated into 24-wells at a density of 2.5 × 105 cells
per well. After 2 h of incubation at 37 °C, nonadherent
cells were removed. The purity of microglia cultures was
assessed by using OX-42 antibody, and more than 95 %
of cells were stained positively. Cells were cultured for
2 days before treatment.
Real-time RT-PCR analysis
The expression of TNF-α and Nur77 gene were quanti-
fied using real-time reverse transcription polymerase
chain reaction (RT-PCR) analysis. Briefly, total RNA was
extracted from microglia cultures with TRIzol® reagent
(Invitrogen). One-step real-time RT-PCR analysis was
performed to determine the expression of genes (Power
SYBR® Green RNA-to-CT
TM 1-step kit, Applied Biosys-
tems, Foster City, CA). The primer sequences are as fol-
lows: for mouse TNF-α, 5′-TTC TGT CTA CTG AAC
TTC GGG GTG ATC GGT CC-3′ and 5′-GTA TGA
GAT AGC AAA TCG GCT GAC GGT GTG GG-3′; for
mouse Nur77, 5′-AGC TTG GGT GTT GAT GTT CC-
3′ and 5′-AAT GCG ATT CTG CAG CTC TT-3′; for
mouse Nurr1, 5′-TCA CCT CCG GTG AGT CTG
ATC-3′ and 5′-TGC TGG ATA TGT TGG GTA TCA
TCT-3′; for mouse NOR-1, 5′-CGC CGA AAC CGA
TGT CA-3′ and 5′-TGT ACG CAC AAC TTC CTT
AAC CA-3′; for mouse β-actin, 5′-GGC TGT ATTCCC CTC CAT CG-3′ and 5′-CCA GTT GGT AAC
AAT GCC ATG T-3′; for rat TNF-α, 5′-CAG GGC
AAT GAT CCC AAA GTA-3′ and 5′-GCA GTC AGA
TCA TCT TCT CGA-3′; for rat Nur77, 5′-CCG GTG
ACG TGC AGC AAT TTT ATG AC-3′ and 5′-GGC
TAG AAT GTT GTC TAT CCA GTC ACC-3′; for rat
β-actin, 5′-CAC CCG CGA GTA CAA CCT TC-3′ and
5′-CCC ATA CCC ACC ATC ACA CC-3′. Threshold
cycle (Ct) value for each test gene was normalized to the
Ct value for the β-actin control from the same RNA prep-
arations. The ratio of transcription of each gene was cal-
culated as 2-(ΔCt), where ΔCt is the difference Ct (test gene)
−Ct (β-actin).
Western blotting
Microglial cells were lysed in M-PER® Mammalian Pro-
tein Extraction Reagent (Pierce, Rockford, IL). Protein
concentration was determined by Bradford assay (Bio-
Rad, Hercules, CA,); 30~50 μg of protein sample was
separated on 10~12 % sodium dodecyl sulfate-
polyacrylamide gel (SDS-PAGE) and transferred to
immobilon polyvinylidene difluoride (PVDF) membranes
(Merck Millipore, Billerica, MA). The membranes were
incubated in Tris-buffered saline (TBST, 0.1 M Tris/
HCl, pH 7.4, 0.9 % NaCl, 0.1 % Tween 20) supplemented
with 5 % dry skim milk for 1 h to block nonspecific
binding. After rinsing with TBST buffer, the membranes
were incubated with primary antibodies against Nur77,
Nurr1, and NOR-1; phosphorylated members of the
MAP kinase family; the specific phosphorylated sites
were IκB-α (Ser32), NF-κB p65 (Ser276, Ser468 and
Ser536), Akt (Ser473), S6K (Thr389), 4E-BP1 (Ser64 and
Thr69), vasodilator-stimulated phosphoprotein (VASP)
(Ser157), and MSK1 (Ser376); and an acetylated site of
NF-κB p65 (Lys310). Antibodies active against all forms
of each mentioned protein, histone deacetylase 1 or β-
actin, were used as internal controls to determine load-
ing efficiency. The membranes were washed three times
with TBST followed by incubation with appropriate
horseradish peroxidase-conjugated secondary antibodies.
The antigen-antibody complex was detected by using an
ECL chemiluminescence detection system (PerkinElmer,
Boston, MA). The intensity of the bands was quantified
with a GS-800 calibrated densitometer (Bio-Rad) and
calculated as the optical density × area of bands.
DNA binding assay
Nuclear extracts were prepared by using the NE-PER®
nuclear and cytoplasmic extraction reagents (Pierce) as
per the manufacturer’s instructions. The DNA binding
assay was performed as described [29] with some modi-
fications. Briefly, 5~10 μg of nuclear extracts were mixed
with poly dI-dC (50 μg/ml) in a binding buffer (10 mM
HEPES, pH 7.9, 50 mM KCl, 0.5 mM EDTA, 0.5 mM
Huang et al. Journal of Neuroinflammation  (2016) 13:78 Page 4 of 20DTT, 3 mM MgCl2, 5 % glycerol, 0.5 mg/ml BSA, 0.05 %
NP-40) and then incubated in 96-well plates coated with
immobilized biotin-labeled oligonucleotides (2 pmol
per/well) for 1 h at room temperature. Following three
washes, primary antibody specific to NF-κB p65 was
added and incubated again at room temperature for 1 h.
Addition of secondary antibody conjugated to horserad-
ish peroxidase was performed prior to the quantification
of NF-κB DNA-binding activity by measuring lumines-
cence (FLx800 Fluorescence Reader, Biotek Instruments,
Inc., Winooski, VT). The following biotin-labeled oligo-
nucleotides were used: the consensus NF-κB, 5′-
CACAGTTG- AGGGGACTTTCCCAGGC-3′; the four
putative NF-κB sequences within the mouse TNF-α
promoter, κB1 (−856): 5′-GGGGGAGGGGAATCC
TTGGAAGAC-3′; κB2 (−659): 5′-GAG- GTCCGT
GAATTCCCAGGGCTG-3′; κB3 (−512): 5′-CAAA
CAGGGGGCTTTCCCTCCT-CA-3′; κB4 (−214): 5′-
GACGGGGAGGAGATTCCTTGATGC-3′.
Transient transfection and luciferase assay
TNF-α promoter luciferase construct (TNF-α-Luc) was
created by ligating a 1.2-kb KpnI-XhoI fragment of the
mouse TNF-α promoter into the pGL3 basic plasmid
(Promega, Madison, WI). The fragment was amplified
by PCR with the following primers: forward, 5′-
CGGGGTACCGATTCTGTCTGCTTGTGTCT-3′ and
reverse, 5′-CGGCTCGAGGTTCTGGAGTTTCTGTT
CTC-3′. NF-κB promoter luciferase construct (NF-κB-
Luc) was purchased from Clontech Laboratories (Palo
Alto, CA) and contains four repeats of consensus NF-κB
binding sequence. Each construct was transfected into
BV-2 cells using TurboFect Transfection Reagent
(Thermo Scientific, Lafayette, CO) following the manu-
facturer’s protocols. At 24 h after transfection, cells were
treated with LPS in the absence or presence of 6-MP for
another 6 h. Luciferase activity of cell lysates was deter-
mined luminometrically by the luciferase assay system
(Promega) as specified by the manufacturer. Each trans-
fection was performed in duplicate, and all experiments
were repeated at least three times. Luciferase activity of
each sample was normalized to the protein content of
the extracts. Luciferase activity from the untreated sam-
ple was arbitrarily set at 1.0 for the calculation of fold
induction.
Chromatin immunoprecipitation
BV-2 cells were pretreated with 50 μM 6-MP for 16 h
followed by stimulation with 100 ng/ml LPS for the indi-
cated times. Cells were cross-linked with 1 % formalde-
hyde and stored at −80 °C before use. Chromatin
immunoprecipitation (ChIP) assays were performed
using SimpleChIP® Enzymatic Chromatin IP kit (Cell
Signaling Technology, Beverly, MA) following themanufacturer’s protocols. Cross-linked chromatin was
enzymatic digested to generate fragments with a length
of approximately 150–900 bp (1 to 5 nucleosomes). The
chromatin was subjected to immunoprecipitation using
the following antibodies: anti-p65, anti-p300, anti-acetyl-
histone H3, and normal rabbit IgG (Abcam). Immuno-
precipitated DNA fragments were collected by Protein G
magnetic beads. DNA/protein complexes were eluted
from the beads and reverse cross-linked at 65 °C for 2 h
in the presence of Proteinase K. Purified DNA were sub-
jected to real-time PCR using primers specific to NF-κB
binding site of mouse TNF-α promoter. The sequences
of the primers used for ChIP and the PCR product size
are as follows: κB1, 5′-GAG AAG TGA CTC CAC TGG
AGG GT-3′ and 5′-ACT GCG GTA CAT CAA CTC
AGA CAT-3′ (−912 to–763, 150 bp); κB2, 5′-AAG GCT
TGT GAG GTC CGT GA -3′ and 5′-AAG TGG CTG
AAG GCA GAG CA-3′ (−675 to–532, 144 bp); κB3, 5′-
ATG CAC ACT TCC CAA CTC TCA AG-3′ and 5′-
CTT CTG AAA GCT GGG TGC ATA AG-3′ (−575
to–457, 119 bp); and κB4, 5′-TCT GGA GGA CAG
AGA AGA AAT G-3′ and 5′-GGT TTG GAA AGT
TGG GGA CAC C-3′ (−353 to–172, 182 bp). The abun-
dance of the immunoprecipitated DNA in a sample was
normalized to the amount of signal in the input DNA.
The values of the untreated cultures or LPS-treated
alone cultures were set to 1.0 or 100 %, respectively.
Immunoprecipitation
Following LPS stimulation, cells were then harvested
with NE-PER® nuclear and cytoplasmic extraction re-
agents. The nuclear extracts (120 μg of protein) were in-
cubated with a rabbit anti-Nur77 or a rabbit anti-p65
antibody with gentle rocking overnight at 4 °C. PurePro-
teomeTM protein G magnetic beads (Merck Millipore)
were added (15 μl of suspension) and rotated for 3 h at
4 °C. After washing the beads with ice-cold immunopre-
cipitation buffer (20 mM Tris, pH 7.5, 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1 % Triton X-100, 2.5 mM
sodium pyrophosphate, 1 mM β-glycerolphosphate,
1 mM Na3VO4, 1 μg/ml leupeptin, 1 mM PMSF), immu-
noprecipitated proteins were eluted in sample buffer and
subjected to Western blotting analyses with anti-Nur77
and anti-P65 antibodies.
RNA interference
Mouse On-TARGET plus® SMARTpool Nur77 siRNA
were obtained from Dhmarcon (Thermo Scientific).
Nonspecific siRNA was used as negative control. BV-2
cells were seeded in 24-well plates for 16 h prior to
transfection. siRNA duplexes were transfected into BV-2
cells using Lipofectamine® RNAiMAX Transfection Re-
agent (Invitrogen) according to the protocol of the
manufacturer. After 48-h transfection, BV-2 cells were
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luciferase reporter construct followed by exposure to
LPS with or without 6-MP pretreatment, and luciferase
activity was assayed. For TNF-α mRNA expression, re-
leased TNF-α assay, or ChIP analysis, cells were pre-
treated with 50 μM 6-MP for 16 h prior to LPS
exposure after siRNA transfection.TNF-α assay
Primary microglia and BV-2 microglia were stimulated
with LPS in the absence or presence of 6-MP, and
supernatants were collected and kept frozen in aliquots
at −80 °C until use. Release of TNF-α was measured
with a commercial enzyme-linked immunosorbent assay
(ELISA) kit from R&D Systems (Minneapolis, MN) ac-
cording to the manufacturer’s instructions.Statistical analysis
All data are expressed as mean ± SEM. Data were ana-
lyzed by one-way ANOVA followed by Scheffe’s test. For
paired analyses, t test was used. A p value less than 0.05
was considered statistically significant.Fig. 1 6-MP attenuates TNF-α production in microglia. a Cells were pretrea
then stimulated with 100 ng/ml LPS for 6 h. TNF-α secretion into the cultu
control and 6-MP pretreated groups were calculated and expressed as perc
independent experiments. *p < 0.05; **p < 0.01 compared with control.
6-MP for 16 h followed by treatment with 100 ng/ml LPS for 6 h (b) o
of TNF-α mRNA (c) was quantified by real-time RT-PCR as described in
independent experiments. *p < 0.05; **p < 0.01 compared with control.
levels of TNF-α in LPS-treated alone BV-2 cells and primary microglia were 16.
mRNA by 6-MP requires de novo protein synthesis. BV-2 cells were pretreated
incubation without or with 6-MP (50 μM) and subsequent LPS stimulation (10
PCR. Data are presented as mean ± SEM for three independent experiments. *
various concentrations of 6-MP for 4 h or 16 h followed by exposure to 100 n
analysis. Data are presented as mean ± SEM for three independent experimenResults
6-MP decreases TNF-α production in LPS-stimulated
microglia
Because TNF-α is a key cytokine that initiates and pro-
motes inflammation in the brain, we tested whether 6-
MP might modulate microglial activation by examining
the effect of 6-MP on LPS-induced TNF-α release in
microglia. Microglia were pretreated with 6-MP for
0.5~16 h prior to stimulation with 100 ng/ml LPS. Inter-
estingly, TNF-α protein levels were significantly reduced
in cells pretreated with 6-MP for 4 h or longer but not
for 0.5 h (Fig. 1a). Furthermore, Fig. 1b shows that LPS-
induced TNF-α release was markedly suppressed by 6-
MP in a dose-dependent manner. 6-MP has been shown
to exert antiproliferative and cytotoxic effects resulting
primarily from the inhibition of purine biosynthesis at
multiple steps and incorporation into nucleic acids as
thioguanine nucleotide [19]. To exclude the possibility
that 6-MP caused cytotoxic effects which led to the de-
crease in TNF-α, MTT assay was used to evaluate the
cell viability following treatment with 6-MP. We found
that the concentrations used in this study did not show
cytotoxic effects (data not shown). To investigateted (P) with vehicle or 50 μM 6-MP for the indicated times, cells were
re medium was analyzed by ELISA. The relative differences between
ent (%) of control. Data are presented as mean ± SEM for three
b, c Cells were pretreated with vehicle or various concentrations of
r 2 h (c). Released TNF-α (b) was measured by ELISA. Expression
the “Methods” section. Data are presented as mean ± SEM for three
The TNF-α content in untreated cultures was not detectable. The
0 ± 0.4 and 2.8 ± 0.3 ng/ml, respectively. d The suppression of TNF-α
with cyclohexamide (CHX, 0.5 μg/ml) or its vehicle 1 h before 16-h
0 ng/ml) for 2 h. TNF-α mRNA expression was analyzed by real-time RT-
*p < 0.01 compared with control. e BV-2 cells were pretreated (P) with
g/ml LPS for 2 h. Total RNA was then extracted for real-time RT-PCR
ts. **p < 0.01 compared with respective control
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following 6-MP exposure is due to suppression of TNF-
α mRNA expression, real-time RT-PCR analysis was per-
formed to assess the TNF-α mRNA levels. The results
showed that 6-MP pretreatment significantly reduced
LPS-induced TNF-α mRNA expression in a dose-
dependent manner (Fig. 1c). Such prolonged pretreat-
ment required for 6-MP’s inhibitory effect suggests that
the effect might be dependent on de novo protein syn-
thesis. To test this hypothesis, the effect of cyclohexi-
mide, a protein synthesis inhibitor, on 6-MP-mediated
inhibition of TNF-α mRNA expression was examined.
Cycloheximide treatment was shown to reverse the sup-
pressive effect of 6-MP on TNF-α mRNA expression
(Fig. 1d), suggesting that a protein induced by the 6-MP
signals likely suppressed TNF-α mRNA synthesis in-
duced by LPS. Additionally, Fig. 1e shows that pretreat-
ment of BV-2 cells with 12.5–50 μM 6-MP for 4 h did
not markedly inhibit TNF-α mRNA expression, whereas
the protein levels of TNF-α were significantly reduced in
cultures pretreated with 50 μM (Fig. 1a). These data
raise the possibility that 6-MP may also exert an ability
to control TNF-α mRNA translation.
6-MP does not affect intracellular Toll-like receptor (TLR)
signaling
LPS induces the production of proinflammatory cyto-
kines through intracellular phosphorylation signaling
cascades activated by TLR4, including MAP kinase and
NF-κB signaling cascade [30–32]. We next determined
whether or not the de novo synthesis proteins induced
by 6-MP exert their ability on suppression of TNF-α
mRNA is by disrupting the TLR signaling. Activation of
three MAPKs, including p38, ERK, and JNK, was ana-
lyzed by Western blotting. As shown in Fig. 2, 6-MP wasFig. 2 6-MP does not inhibit LPS-induced activation of MAPKs signals. BV-2
MP (50 μM) for 16 h and stimulated with LPS (100 ng/ml) for the indicated
to determine LPS-induced p38, ERK, and JNK activation in the absence or p
independent experimentsnot able to block LPS-induced phosphorylation of three
MAPKs in microglia. Activation of the IκB kinase (IKK)
complex depends on phosphorylation and has been
demonstrated to be critical for NF-κB activation. After
phosphorylation of IκB-α by the IKK complex, IκB-α is
degraded and releases NF-κB [33]. Therefore, we deter-
mined the effect of 6-MP on IκB-α phosphorylation and
degradation. 6-MP failed to suppress LPS-induced IκB-α
phosphorylation and degradation (Fig. 3a), suggesting
that the action of 6-MP may be mediated through im-
pairment of the downstream signaling of IKK activation
and IκB-α degradation. Upon TLR signaling, the tran-
scription factor NF-κB is translocated into the nucleus
and upregulated cytokine mRNA transcription. The nu-
clear localization of the p65 subunit of NF-κB was also
unaffected by 6-MP pretreatment (Fig. 3b).
6-MP downregulates LPS-stimulated transcriptional activ-
ity of TNF-α promoter
TNF-α gene transcription is largely predicated by
binding of NF-κB to its cis regulatory elements within
the TNF-α promoter [34]. Four putative κB sites have
been identified in the murine TNF-α promoter. These
sites are termed κB1 to −4 and are located at the nucleo-
tide positions −856, −659, −512, and −214, respectively
([35, 36], Accession No.: NC_000083.6). As mentioned
above, 6-MP pretreatment did not appear to affect
MAPK and NF-κB activation, we then tested a possibility
that 6-MP might inhibit TNF-α transcription by directly
interfering with NF-κB binding to its DNA element. To
explore this possibility, nuclear proteins were extracted
from BV-2 cells pretreated with 6-MP and stimulated
with LPS. ELISA-based assay was performed to assess
NF-κB p65 binding to four putative κB sequence located
within the mouse TNF-α promoter (Fig. 3c) as well as tocells (a) and primary microglia (b) were pretreated with vehicle or 6-
times. Whole cell extracts were prepared. Western analysis was used
resence of 6-MP. The immunoblots are representative of three
Fig. 3 6-MP decreases LPS-induced transactivation of NF-κB and TNF-α promoter. BV-2 cells were preincubated with vehicle or 6-MP (50 μM) for
16 h before stimulation with 100 ng/ml LPS for the various times indicated. Whole cell lysates and nuclear extracts were prepared. a IκB-α
degradation is not suppressed by 6-MP. Western analysis was used to determine total and phosphorylated IκB-α proteins in whole cell
extracts. b Translocation of p65 from cytosol to the nucleus was determined by immunoblotting. β-Actin and histone deacetylase 1
(HDAC1) immunoblotting were performed to monitor loading for cytosol and nuclear proteins, respectively. c Putative 4-κB sites within
the mouse TNF-α promoter (κB1 to 4) and a consensus κB sequence are schematically depicted. The underlines indicate the binding
sequences for NF-κB. d Cells were pretreated with vehicle or 6-MP (50 μM) for 16 h before stimulation with 100 ng/ml LPS for 60 min.
Nuclear proteins were isolated. ELISA-based measurement of p65 DNA binding was analyzed as described in the “Methods” section. e, f
Cells were transfected with a 4XNF-κB (e) or TNF-α promoter (f) luciferase construct; 24 h post-transfection, cells were preincubated with
vehicle or various concentrations of 6-MP for 16 h before stimulation with 100 ng/ml LPS for 6 h. Luciferase activity is presented as a fold
of control. Data are presented as mean ± SEM for four independent experiments. *p < 0.05; **p < 0.01 compared with LPS alone
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a marked increase in amount of p65 bound to all oligo-
nucleotides tested (Fig. 3d). Pretreatment with 6-MP had
no inhibitory effects on LPS-induced p65 DNA binding,
indicating that 6-MP does not change the binding of p65
to the κB sites in an in vitro assay.
To further assess whether the suppressive effect of 6-
MP on TNF-α gene transcription is mediated by down-
regulating TNF-α promoter activity, we transient trans-
fection BV-2 cells with a TNF-α promoter-luciferase
construct (TNF-α-Luc). Because TNF-α promoter activ-
ity is largely dependent on κB elements, we also assessed
the effects of 6-MP on NF-κB promoter using a reporter
gene with 4× κB sequences (NF-κB-Luc). LPS treatment
alone prominently elicited transcriptional activity of the
TNF-α and NF-κB consensus promoter, and this effect
was significantly attenuated by concomitant 6-MP pre-
treatment (Fig. 3e, f ). These findings confirm that theinhibitory effect of 6-MP on TNF-α gene expression is,
at least partially, mediated by inhibition of NF-κB trans-
activation activity.
6-MP inhibits NF-κB p65 phosphorylation and acetylation
NF-κB activation, characterized by phosphorylation of
specific amino acid residues in the p65 subunit, is one
important prerequisite for transactivation of the target
genes [37–39]. Therefore, one possible mechanism by
which 6-MP may control LPS-induced NF-κB activity
may be through direct phosphorylation of NF-κB. We
included in our analysis the assessment of phosphoryl-
ation of p65. In control BV-2 cells, LPS stimulation re-
sulted in enhanced phosphorylation of p65 at Ser276,
468, and 536 (Fig. 4a). Cells pretreated with 6-MP
showed a compromised induction of phosphorylation at
Ser276 but not 468 or 536 upon treatment with LPS.
Zhong et al. [40] have proposed that the catalytic
Fig. 4 6-MP inhibits NF-κB p65 phosphorylation at Ser276 and
acetylation at Lys310. BV-2 cells were pretreated with vehicle or 6-MP
(50 μM) for 16 h and then stimulated with LPS (100 ng/ml) for the
indicated times. Whole cell lysates were prepared and subjected to
western blotting using antibodies specific for phosphorylated (Ser276,
468, and 536) (a), acetylated (Lys310) (b), or total forms of p65. Data are
presented as mean ± SEM for three independent experiments. *p< 0.05;
**p< 0.01 compared with respective cultures treated with LPS alone
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through direct interaction with IκB in the NF-κB/IκB
complex. LPS-induced degradation of IκB-α releases the
kinase to phosphorylate the vicinal substrate p65 at
Ser276. To determine if this mechanism for phosphoryl-
ation of p65 is suppressed by 6-MP, we assessed the
LPS-induced PKA activation by detecting the phosphor-
ylation of VASP at Ser157, which is a typical surrogate
of PKA activity [41]. The results showed that 6-MP had
no inhibitory effect on LPS-induced VASP phosphoryl-
ation (Additional file 1: Figure S1). This is consistent
with the observations that 6-MP did not inhibit IκB-α
degradation induced by LPS (Fig. 3a). Furthermore, the
nuclear kinase mitogen- and stress-activated protein
kinase-1 (MSK1) is another candidate for phosphoryl-
ation of this site [42, 43]. To determine further
whether 6-MP inhibits activation of MSK1, BV-2 cells
were stimulated with LPS in the absence or presence
of 6-MP pretreatment. Western blot analysis showed
that LPS-provoked phosphorylation (activation) of
MSK1 was not affected by 6-MP (Additional file 1:
Figure S1). The data suggest that 6-MP’s inhibitory
action on phosphorylation of p65 at Ser276 is not
likely to be mediated through impairment of the PKA
or MSK1 activation.
In addition, NF-κB signaling is also modulated by
post-translational modifications, including reversible
acetylation of the p65 subunit [44]. Full transcrip-
tional activity of p65 requires acetylation of Lys310
[45]. Using an antibody specific for acetylated
Lys310, we found that LPS induced increased levels
of acetylated p65 (Fig. 4b). Treatment with 6-MP
diminished levels of p65 with acetylated Lys310.
These results suggest that 6-MP downregulates NF-
κB activation, possibly by inhibiting phosphorylation
and acetylation of p65 on Ser276 and Lys310,
respectively.
6-MP attenuates recruitment of p65 and the coactivator
p300 to the TNF-α promoter and modifies histone H3
acetylation
6-MP treatment was shown to reduce TNF-α mRNA
expression and TNF-α promoter activity. To provide
further support for the hypothesis that 6-MP modu-
lates LPS-induced endogenous transcription of TNF-
α, a ChIP assay was performed to confirm 6-MP ac-
tion on the interactions of p65 with the mouse TNF-
α promoter region. The ChIP assay revealed a time-
dependent recruitment of the p65 subunit of NF-κB
to the TNF-α promoter region of four putative κB
sites after LPS stimulation (Fig. 5a). Moreover, the re-
duced LPS-induced occupancy of p65 at TNF-α pro-
moter was observed in cultures pretreated with 6-MP
(Fig. 5d). Regulation of NF-κB activity has also been
Fig. 5 6-MP reduces LPS-induced p65 and coactivator p300 recruitment and histone H3 acetylation at the TNF-α promoter. a–c BV-2 cells were
stimulated with 100 ng/ml LPS for the indicated times and chromatin immunoprecipitation (ChIP) assays were performed as described in the
“Methods” section. The TNF-α promoter regions encompassing κB1-κB4 were targeted for ChIP analyses assessing associations of p65 (a), p300
(b), and acetylated histone H3 (Ac-H3) (c). The abundance of the immunoprecipitated DNA in a sample was normalized to the amount of signal
in the input DNA. The values of the untreated samples were set to 1.0. Data are presented as mean ± SEM for three independent experiments.
d–f BV-2 cells were pretreated with vehicle or 6-MP (50 μM) for 16 h followed by exposure to 100 ng/ml LPS for 60 min. ChIP analyses were
carried out with anti-p65 (d), anti-p300 (e), and anti-Ac-H3 (f) antibodies. The values of the LPS alone-treated samples were set to 100 %. Data are
presented as mean ± SEM for five independent experiments. *p < 0.05; **p < 0.01 compared with respective LPS alone
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tional coactivators. Cyclic-AMP response element
binding protein (CREB)-binding protein (CBP) and its
homologue p300 are transcriptional coactivators
known to interact with p65 [46, 47]. Additionally, his-
tone acetylation of lysine residues requires the activ-
ities of histone acetyltransferases, such as CBP/p300,
which are important in relaxing the compact struc-
ture of nucleosomes [48]. The effect of 6-MP on the
recruitment of coactivator p300 to the TNF-α pro-
moter and LPS-induced histone modifications were
analyzed. p300 was weakly associated with the TNF-α
promoter in untreated BV-2 cells, and LPS stimula-
tion strongly promoted recruitment of p300 to the
κB2 and κB4 sites at 30–120 min, whereas the occu-
pancy of p300 at κB1 and κB3 was slightly increased
(Fig. 5b). Similar to p65, 6-MP inhibited LPS-induced
recruitment of p300 to the four κB sites of TNF-α
promoter (Fig. 5e). In addition, in untreated cells, his-
tone H3 was weakly acetylated on the TNF-α pro-
moter, and acetylation of histone H3 was enhanced in
a time-dependent manner following LPS exposure
(Fig. 5c). Enrichment of Ac-H3 induced by LPS was
also decreased in 6-MP-pretreated cells (Fig. 5f ).
These findings collectively suggest that 6-MP may
keep promoter in a deacetylated state following treat-
ment with LPS and reduce the association of p65-
p300 complex with the promoter to inactivate the
transcription of TNF-α gene.Nur77 is required for 6-MP-induced suppression of TNF-α
production
Our investigation demonstrated that the inhibitory effects
of 6-MP was shown to be dependent on de novo protein
synthesis. Previous studies reported that 6-MP increases
the transactivation of the NR4A orphan nuclear receptors
in several cell types [24, 25, 49]. These receptors have
been shown to resolve inflammation [50–53]. To deter-
mine whether 6-MP induces NR4A receptors expression
in microglia, real-time RT-PCR analysis and western blot-
ting were performed to assess the NR4A receptors mRNA
and protein levels, respectively. The results showed that 6-
MP upregulated Nur77 and Nurr1, but had no effect on
NOR-1 mRNA expression in BV-2 cells (Fig. 6a,
Additional file 2: Figure S2). In contrast to Nur77 (Fig. 6b),
the change of Nurr1 protein level induced by 6-MP was
not observed in our experiments (Additional file 2: Figure
S2). These findings indicate that the protein levels of all
three NR4A receptors are not simultaneously increased by
6-MP in BV-2 cells. 6-MP-elevated Nur77 expression was
further validated in primary microglia (Fig. 6c, d). Nur77
has been reported to exert an anti-inflammatory property
in various cell and animal models [52–56]. To substantiate
the significance of 6-MP-induced Nur77 in microglial acti-
vation, we performed loss-of-function studies, using the
RNA interference technique. Knockdown of Nur77 ex-
pression in 6-MP-pretreated BV-2 cells (Fig. 6e) led to a
significant decrease in 6-MP-mediated inhibition of TNF-
α expression (Fig. 6f, g). Furthermore, the inhibitory effect
Fig. 6 Upregulated Nur77 is involved in 6-MP-mediated inhibitory effect on TNF-α production. BV-2 cells (a, b) and primary microglia (c, d) were
treated with vehicle or various concentrations of 6-MP for 1 h (a, c) or 16 h (b, d). The expression of Nur77 mRNA (a, c) was quantified by real-
time RT-PCR. Nuclear extracts were prepared and subjected to western blotting (b, d) using antibody specific for Nur77. HDAC1 immunoblotting
was performed to monitor loading. Data are presented as mean ± SEM for three independent experiments. *p < 0.05; **p < 0.01 compared with
control. e BV-2 cells were transfected with control or Nur77 siRNA for 48 h followed by treatment with 6-MP (50 μM) for 1 h (left) or 16 h (right).
Total RNA and nuclear proteins were extracted. Expression levels of Nur77 mRNA and protein were analyzed by real-time RT-PCR (left) and
western blotting (right), respectively. **p < 0.01 compared with 6-MP-treated control siRNA transfected cells. f, g After siRNA transfection, BV-2 cells
were pretreated with 25 and 50 μM 6-MP for 16 h followed by treatment with LPS for another 2 h (f) or 6 h (g). Analyses of TNF-α mRNA
expression and released TNF-α were performed as described in Fig. 1. Data are presented as mean ± SEM for three independent experiments.
LPS-induced TNF-α production in control siRNA and Nur77 siRNA transfected cells were 25.1 ± 2.4 and 27.0 ± 3.5 ng/ml, respectively. *p < 0.05;
**p < 0.01 compared with 6-MP-pretreated control siRNA transfected cells. h, i Nur77 contributes to 6-MP-mediated inhibition of NF-κB and TNF-α
promoter transcriptional activities. After siRNA transfection, NF-κB (h) or TNF-α promoter (i) luciferase construct was transfected into BV-2 cells for
24 h. The transfected cells were pretreated with 50 μM 6-MP for 16 h followed by treatment with LPS for another 6 h. Luciferase activity from the
non-stimulated cells transfected with control siRNA was arbitrarily set at 1.0 for the calculation of fold. Data are presented as mean ± SEM for four
independent experiments. **p < 0.01 compared with 6-MP-pretreated control siRNA transfected cells
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tivity was relieved in cells transfected with Nur77 siRNA
(Fig. 6h, i). Thus, downregulation of Nur77 showeddefective 6-MP-mediated suppression of LPS-induced
TNF-α production, demonstrating that Nur77 contributes
to 6-MP’s inhibitory effects.
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scriptional activity by directly interacting with p65 to
weaken its binding to DNA [57, 58]. Therefore, the
physical protein-protein interaction between Nur77 and
p65 was examined. Following LPS stimulation, Nur77
and p65 showed interaction in immunoprecipitation (IP)
assays and the amount of p65 (or Nur77) that precipi-
tated with Nur77 (or p65) was enhanced by 6-MP
(Additional file 3: Figure S3). The results of IP assays are
not consistent with the fact that 6-MP has no influence
on p65 binding to DNA, suggesting that the increased
Nur77-p65 interaction by 6-MP might be not yet suffi-
cient to directly block the binding of p65 to its response
element. To further investigate whether Nur77 is re-
sponsible for the 6-MP’s actions on inhibition of p65
post-translational modifications, we knock down the ex-
pression of Nur77 by using specific small interfering
RNA. As shown in Fig. 7a, b, 6-MP-mediated inhibition
of p65 phosphorylation at Ser276 and acetylation at
Lys310 were reversed after knockdown of Nur77. Fur-
thermore, ChIP assays demonstrated that downregula-
tion of Nur77 could restore 6-MP-mediated reduction of
p65, but not p300, recruitment and histone H3 acetyl-
ation at TNF-α promoter regions (Fig. 7c–e). Our results
provide evidence for 6-MP impact on NF-κB pathway,
likely via Nur77-mediated inhibition of p65 phosphoryl-
ation and acetylation, and an epigenetic regulation
mechanism.
6-MP blocks LPS-induced TNF-α production by inhibiting
PI3-kinase/Akt/mTOR signaling
The post-transcriptional regulation involving transla-
tional efficiency appears to play a critical role in the
regulation of TNF-α expression [59, 60]. As mentioned
above, the reduction in TNF-α mRNA levels caused by
6-MP was not proportional to the reduction in protein
levels (Fig. 1b, c), suggesting that a post-transcriptional
regulation is involved in the inhibitory effect of 6-MP. In
addition, pretreatment with 6-MP (50 μM) for 4 h did
not markedly decrease the levels of TNF-α mRNA,
whereas the protein levels that were significantly re-
duced further supported this possibility. The signaling
pathway, PI3-kinase (PI3K), is well known to control
translation, involving signaling by Akt/protein kinase B
and the mammalian target of rapamycin (mTOR) [61].
Activation of mTOR complex 1 (mTORC1) initiates the
protein synthesis machinery via the phosphorylation of
downstream targets p70 ribosomal protein S6 kinase
(S6K) and the eukaryotic initiation factor 4E binding
protein 1 (4E-BP1) [62, 63]. To test whether the PI3K
pathway is regulated by 6-MP, we examined the phos-
phorylation of Akt, a well known target of PI3K. LPS
stimulation resulted in a time-dependent phosphoryl-
ation of Akt (Fig. 8). Pretreatment of BV-2 cells with 6-MP markedly suppressed Akt phosphorylation caused by
LPS. S6K is a common downstream effector of mTORC1
and plays a direct role in regulating translation [64]. Fur-
thermore, activation of mTORC1 also results in phos-
phorylation of 4E-BP1 at Thr36, Thr45, Ser64, and
Thr69 sites and the release of 4E-BP1 from eukaryotic
initiation factor (eIF) 4E [65, 66], which is a limiting step
in translation initiation. Therefore, we sought to deter-
mine whether 6-MP also regulates LPS-induced S6K and
4E-BP1 phosphorylation. Fig. 8 shows that LPS induced
a time-dependent phosphorylation of S6K and 4E-BP1,
which correlated with the kinetics of Akt activation by
LPS. 6-MP pretreatment led to suppression of LPS-
induced S6K phosphorylation and retention of 4E-BP1
in its active (hypophosphorylated) state. The γ-form is
positive for phospho-Ser64 and contains all phosphory-
lated sites representing the hyperphosphorylated state.
4E-BP1 dissociation from eIF4E is generally associated
with γ-form [67, 68]. We found that 6-MP also pre-
vented the γ-form of 4E-BP1 accumulation caused by
LPS (Fig. 8). Moreover, the investigation of the dose-
response relationship for 6-MP-mediated blockade of
PI3K-Akt-mTOR signaling pathway was performed over
concentrations ranging from 6.3 to 50 μM. As illustrated
in Fig. 9a, pretreatment of BV-2 cells with 6-MP led to a
dose-dependent decrease in LPS-induced phosphoryl-
ation of Akt, S6K, and 4E-BP1 and accumulation of γ
form of 4E-BP1. The 6-MP concentration required to
achieve significant inhibition started between 6.3 and
12.5 μM, and the effect was more conspicuous at
50 μM. Similar findings were observed with LPS-
stimulated primary microglia, where 6-MP pretreatment
inhibited PI3K/Akt/mTOR signaling (Fig. 9b).
In LPS-stimulated microglia, inactivation of Akt using
a PI3K inhibitor has been shown to attenuate TNF-α
production by preventing translation of mRNA [28]. We
next used the mTOR inhibitor rapamycin to investigate
the role of mTOR in the 6-MP-mediated decrease in
TNF-α production. LPS-induced S6K phosphorylation in
BV-2 cells was markedly abolished by rapamycin
(Fig. 10a). In addition, rapamycin also blocked LPS-
induced phosphorylation of 4E-BP1, leading to attenu-
ation of the γ form of 4E-BP1 accumulation (Fig. 10a).
Furthermore, LPS-induced TNF-α secretion was inhib-
ited by rapamycin in a dose-dependent manner
(Fig. 10b), which correlates with the decreased level of
phosphorylated S6K and the γ form of 4E-BP1. However,
rapamycin treatment had no inhibitory effect on LPS-
induced TNF-α mRNA expression and TNF-α/consen-
sus NF-κB promoter activity (Fig. 10c, d). These results
suggest that downregulation of PI3K/Akt/mTOR signal-
ing might contribute, at least partially, to the 6-MP-
mediated decrease in TNF-α production after LPS
exposure.
Fig. 7 Nur77 is required for 6-MP-mediated inhibition of p65 post-translational modifications, p65 recruitment, and histone H3 acetylation. BV-2
cells were transfected with control or Nur77 siRNA for 48 h. Cells were pretreated with 50 μM 6-MP for 16 h followed by stimulation with 100 ng/
ml LPS for 20 min (a) or 60 min (b–e). The levels of phosphorylated p65 (Ser276) (a) and acetylated p65 (Lys310) (b) were determined by western
blotting. ChIP assays were performed with anti-p65 (c), anti-p300 (d), and anti-Ac-H3 (e) antibodies. The detection of the immunoprecipitated
TNF-α promoter was analyzed by PCR with promoter-specific primers. *p < 0.05; **p < 0.01 compared with 6-MP-pretreated control siRNA
transfected cells
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In chronic neurodegenerative diseases, microglial activa-
tion has been demonstrated to be an early sign that
often precedes and triggers neuronal death [1–3]. There-
fore, downregulation of microglia-mediated inflamma-
tion may offer prospective clinical therapeutic benefitsfor neuroinflammation-related neurodegenerative disor-
ders. 6-MP, derived from the prodrug azathioprine, is
applied as an immunosuppressive drug to treat systemic
lupus erythematosus and inflammatory bowel diseases,
such as Crohn’s disease [18]. We herein speculated that
the 6-MP-mediated anti-inflammatory effects might not
Fig. 8 6-MP blocks PI3K/Akt/mTOR signaling. BV-2 cells were pretreated with vehicle or 6-MP (50 μM) for 4 h and then stimulated with LPS
(100 ng/ml) for the indicated times. Western analysis was used to determine total and phosphorylated Akt, S6K and 4E-BP1 proteins in whole cell
extracts. Data are presented as mean ± SEM for three independent experiments. *p < 0.05; **p < 0.01 compared with respective LPS alone
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microglial inflammatory responses could be downregu-
lated through decreasing TNF-α secretion in LPS-
stimulated microglia by 6-MP. In line with our results,
6-MP has been shown to robustly suppress MCP-1 ex-
pression in primary macrophages stimulated with LPS
[26]. Using oxidized low-density lipoprotein (oxLDL)-
treated RAW264.7 macrophage, Shao et al. [69] reported
that MCP-1 and TNF-α mRNA expression are inhibited
by 6-MP. Furthermore, 6-MP also exhibits an anti-
inflammatory effect on endothelial cells [22, 70]. Our
findings underscore the importance of 6-MP in regula-
tion of inflammation and extend the role of 6-MP to a
modulator of microglial activation.
Blockade of gene transcription in stimulated inflam-
matory cells is often due to one or multiple interrup-
tions in the signaling transduction from the stimuli to
the corresponding transcriptional cytokines. MAPKs
are known to play a critical role in cytokine produc-
tion [30, 71]. To understand the molecular mecha-
nisms underlying the inhibitory effect of 6-MP, we
studied the effect of 6-MP on LPS-induced activation
of MAPKs. We found that 6-MP pretreatment did
not inhibit LPS-induced phosphorylation of all three
MAPKs. The major mechanism of action of 6-MP is be-
lieved to be inhibition of purine synthesis, and this effect
is observed at a relatively high dose of 6-MP (500 μM)
[72]. Other described mechanisms of action of 6-MPinclude inhibition of specific GTP-dependent proteins
Rac1 and Rac2 in CD4+ T cells, which leads to blockade
of T cell activation [21]. In addition, recent studies show
that 6-MP inhibits Rac1 activation and thus subsequently
attenuates the JNK signaling cascade, thereby decreasing
inflammation in TNF-α-treated endothelial cells [22, 70].
Furthermore, 6-MP also has Rac1/JNK-dependent anti-
inflammatory effect in macrophages exposed to inter-
feron γ (IFN-γ) [23]. Our study found no reduction in
JNK phosphorylation in microglia pretreated with 6-MP.
Possible interpretations of our findings are that 6-MP in-
hibits phosphorylation of JNK in a cell type- and
stimulus-specific manner.
The activation of Rac1 is inhibited by 6-MP, but with
limited specificity, because not all immunosuppressive
effects of 6-MP involve Rac1 inhibition [22, 23, 70]. 6-
MP has been identified as an activator of orphan nuclear
receptor Nur77 to increase the protein level and the
transactivation function in several cell types [25, 49, 73].
Nur77 expression can be rapidly induced in monocytes
and macrophages by a variety of inflammatory stimuli,
such as TNF-α, LPS, and IFN-γ [52, 74]. The anti-
inflammatory property of Nur77 has been demonstrated
in various cell and animal models. In macrophages, over-
expression of Nur77 reduces the expression of several
inflammatory cytokines in response to LPS, TNF-α, and
oxLDL [52, 69]. Moreover, Nur77 elevation suppresses
TNF-α- and IL-1β-induced ICAM-1 and VCAM-1
Fig. 9 Dose-dependently inhibitory effect of 6-MP on activation of PI3K/Akt/mTOR signaling cascades. BV-2 cells (a) or primary microglia (b) were
pretreated with vehicle or various concentrations (a) or 50 μM (b) of 6-MP for 4 h followed by exposure to LPS (100 ng/ml) for 60 min. Western
analysis was performed as described in Fig. 8. Data are presented as mean ± SEM of three independent experiments. *p < 0.05; **p < 0.01
compared with LPS alone
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Nur77 shows enhanced atherosclerosis, 2,4,6-trinitro-
benzene sulfonic acid-induced colitis, and OVA-induced
allergic airway inflammation [54–56]. Therefore, Nur77
may act as a molecular target for modulating of inflam-
mation and Nur77 agonists may provide an effective
treatment for inflammatory diseases. Herein, we found
that the expression of Nur77 mRNA and protein were
increased following 6-MP treatment in microglial cells.Furthermore, knockdown of Nur77 was shown to relieve
the 6-MP-mediated inhibitory effect on LPS-induced
TNF-α release. This is in agreement with a previous
study reporting that Nur77 activation is responsible for
6-MP-mediated decrease in MCP-1 and TNF-α mRNA
expression in oxLDL-stimulated macrophages [69]. Our
findings suggest that in microglial cells, 6-MP mediates
its anti-inflammatory function through, at least partially,
upregulation of Nur77.
Fig. 10 The mTOR inhibitor rapamycin reduces LPS-induced-TNF-α production through preventing mTOR signaling-mediated mRNA translation.
BV-2 cells were pretreated with vehicle or various concentrations of rapamycin for 30 min followed by treatment with 100 ng/ml LPS for 60 min
(western blotting), 2 h (TNF-α mRNA), or 6 h (TNF-α protein). Western analysis (a) was performed as described in Fig. 8. Released TNF-α (b) was
measured by ELISA. The expression of TNF-α mRNA (c) was quantified by real-time RT-PCR. Data are presented as mean ± SEM of three independ-
ent experiments. **p < 0.01 compared with LPS alone. The level of TNF-α in cells treated with LPS alone was 18.1 ± 2.3 ng/ml. d. LPS-induced NF-
κB or TNF-α promoter activity is not altered by rapamycin. Following transfection of BV-2 cells with NF-κB or TNF-α promoter luciferase construct,
cells were pretreated with various concentrations of rapamycin for 30 min prior to treatment with LPS (100 ng/ml) for 6 h. Luciferase activity is
presented as a fold of control. Data are presented as mean ± SEM of three independent experiments
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of proinflammatory cytokines expression [30, 31, 33, 71].
IκB masks p65 in the cytosol to prevent NF-κB-
associated transcription in the nucleus. IκB is ubiquiti-
nated for degradation upon phosphorylation by IKKs,
which activates NF-κB. It has been proposed that Nur77modulates inflammatory gene expression at least in part
through transrepression of NF-κB in multiple cell sys-
tems [53–58]. In human umbilical vein endothelial cells,
elevated expression of Nur77 results in the increase of
IκBα expression and attenuation of TNF-α-induced
translocation of p65 [53]. Knockdown of Nur77
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NCI-H292 lung epithelial cells [56]. However, these ac-
tions seem to be cell line and stimuli dependent. Fur-
thermore, another mechanism was reported that NF-κB
activity is downregulated through a direct Nur77 inter-
action with p65 to block its binding to the κB element
[57, 58]. Very recently, Calvayrac et al. [51] have shown
that NOR-1 overexpression prevents LPS-induced
MAPKs activation in human vascular smooth muscle
cells. 6-MP downregulated the expression of TNF-α
mRNA in microglial cells upon LPS stimulation; how-
ever, the activation of MAPKs and the IκBα phosphoryl-
ation and degradation as well as the nuclear
translocation did not seem contingent on 6-MP effects.
The association of p65 with Nur77 was enhanced by 6-
MP, whereas the difference in p65 binding to its re-
sponse element in vitro was not observed between con-
trol cells and cells pretreated with 6-MP. Possible
interpretation of our findings is that the increased
amount of Nur77-p65 complex might be not yet enough
to directly alter the DNA binding in our experimental
conditions. Although the early steps leading to NF-κB
activation were unaffected by 6-MP, our results showed
that upregulated Nur77 was contributed to 6-MP-
mediated inhibition of p65-dependent transcription.
These findings suggest that 6-MP-induced Nur77 regu-
lates NF-κB in LPS-stimulated microglia through reduc-
tion of transactivation activity of p65.
Once activated, NF-κB transcriptional activity is fur-
ther regulated by inducible post-translational modifica-
tions, including phosphorylation and acetylation [33, 45].
A number of different phosphorylation sites have been
identified on the p65 subunit. This phosphorylation is
essential for NF-κB nuclear transportation, subunit
dimerization, DNA binding, and finer regulation of NF-
κB transcriptional activity [37–39]. Furthermore, prior
studies implicated CBP/p300 as a critical regulator of
NF-κB activity and showed that recruitment of CBP was
enhanced by phosphorylation of p65 at Ser276 [37, 75].
PKA has been shown to be associated with the phos-
phorylation of p65 at Ser276 in response to LPS in mur-
ine 70Z/3 pre-B cells [40]. In TNF-α- or IL-1β-treated
human HEK293 and murine L929sA cells, MSK1 is re-
sponsible for this phosphorylation [42, 43]. Despite the
fact that neither PKA nor MSK1 activation seemed to be
abolished by 6-MP, our data showed that 6-MP inhibited
LPS-induced phosphorylation of p65 at Ser276 and de-
creased binding of p300 at the TNF-α promoter. A pre-
vious study showed that PKA is not to be a substantial
factor for phosphorylation of this site in LPS-stimulated
RAW264.7 macrophages [76]. Whether LPS-induced
p65 phosphorylation at Ser276 in microglia involves
PKA activation needs further investigation. These find-
ings lead us to deduce that other kinases (as yetunidentified) may be involved in Ser276 phosphorylation
in LPS-stimulated microglia, which could be influenced
by 6-MP. Blockade of 6-MP-mediated repression by
knockdown of Nur77 restored LPS-induced p65
phosphorylation at Ser276, whereas the reduced occu-
pancy of p300 at the TNF-α promoter was not reversed.
These results suggest that in microglia, phosphorylation
of p65 at Ser276 might be necessary but not sufficient
for p300 recruitment to TNF-α promoter. Indeed, post-
translational modifications of CBP/p300, such as methy-
lation, have also been shown to influence its binding to
transcription factors [77, 78]. Site-specific acetylation of
p65 regulates discrete biological actions of the NF-κB
complex [44, 45]. Acetylation of lysine 310 has been
shown to be required for full transcriptional activity of
p65. In the nucleus, p65 associates with p300/CBP tran-
scriptional co-activators. It appears that the major effect
of CBP/p300 on NF-κB-dependent transcription is via
acetylation of proteins and histones in the transcrip-
tional apparatus and chromatin remodeling [45, 48].
Nur77 has been found to interact with p300 and nega-
tively regulate its histone acetyltransferase activity,
resulting in suppression of the acetylation and transcrip-
tional activity of many p300-regulated transcription fac-
tors, e.g., NF-κB p65 [79]. Furthermore, the p300-
induced histone H3 acetylation is also repressed by the
presence of Nur77, suggesting that Nur77 would affect
general transcription machinery through chromatin re-
modeling [79]. In the present study, the addition of 6-
MP decreased levels of acetylated p65 and reduced accu-
mulation of Ac-H3 at the TNF-α promoter following
LPS stimulation and downregulation of Nur77 reversed
this inhibitory effect. Taken together, our data suggest
that 6-MP suppresses TNF-α expression through, at
least in part, Nur77-mediated downregulation of NF-κB
transcriptional efficiency by inhibiting p65 phosphoryl-
ation and acetylation. Moreover, upregulated Nur77 is
also involved in 6-MP-mediated decrease of acetylated
histone H3 at TNF-α promoter, ultimately leading to
compacting chromatin structures and impairing binding
of p65 to induce TNF-α gene expression.
It is known that the post-transcriptional regulation
involving translational efficiency contributes to the
modulation of TNF-α expression [59, 60]. Our study
showed that 6-MP-mediated reduction of TNF-α mRNA
levels is not proportional to the protein production.
Therefore, these results suggest that 6-MP’s inhibitory
effect on TNF-α production may involve a translational
event. LPS-induced activation of MAPK is shown to in-
fluence TNF-α gene expression at the level of translation
[60, 80]. The data presented in this study showing that
LPS-induced activation of MAPK remain unaltered fol-
lowing 6-MP pretreatment. We therefore tend to specu-
late that another mechanism controlling the TNF-α
Huang et al. Journal of Neuroinflammation  (2016) 13:78 Page 17 of 20mRNA translation might be involved in 6-MP-mediated
reduction of TNF-α protein. The PI3K/Akt/mTOR sig-
naling pathway has been shown to play an important
role in the modulation of translation [61, 65, 66]. 4E-
BP1 is a direct target of mTORC1, which is known to
control 4E-BP1 activity through hyperphosphorylation of
this protein [65, 66]. 4E-BP1 phosphorylation is an im-
portant step in controlling the rate of initiation of transla-
tion in mammalian cells [61]. Phosphorylation of 4E-BP1
dissociates it from eIF4E, relieving the translational inhib-
ition. Moreover, S6K is another downstream effector of
mTORC1 and also plays a direct role in regulating transla-
tion [64]. In this report, we found that pretreatment withFig. 11 Proposed model for 6-MP inhibition of LPS-induced TNF-α express
phosphorylation of p65 at Ser276, either in the cytoplasm by PKAc or in th
Nur77 subsequently attenuates p65 phosphorylation (S276) by inhibiting a
activity to limit transcriptional activation of p65. Furthermore, Nur77 blocks
to compacting chromatin structures and impairing binding of p65. Both ev
hand, the inhibitory action of 6-MP also occurs via inactivation of PI3K/Akt/6-MP resulted in attenuation of LPS-induced Akt phos-
phorylation and inhibition of mTORC1 activity, which
was confirmed by a significant decrease in 4E-BP1 and
S6K phosphorylation. Additionally, inhibition of mTOR
activity by rapamycin was shown to reduce the production
of TNF-α protein but had no effect on mRNA levels.
These data are consistent with a recent report showing
that in LPS-stimulated macrophages, a second-generation
mTOR kinase inhibitor INK128 suppresses TNF-α pro-
duction by downregulating TNF-α biosynthesis [81]. The
present results suggest that the inhibitory effects of 6-MP
on TNF-α production are also acted at translational level
by blocking PI3K/Akt/mTOR signaling.ion. Release of NF-κB dimmers following LPS stimulation is linked to
e nucleus by MSK1. In microglia, 6-MP upregulates Nur77 expression.
yet unidentified kinase and acetylation (K310) by dampening p300
the acetylation of histone H3 at TNF-α promoter, ultimately leading
ents reduce the LPS-induced TNF-α gene transcription. On the other
mTOR signaling to downregulate translation
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In summary, a schematic overview of the mechanisms
by which 6-MP inhibits TNF-α expression is presented
in Fig. 11. 6-MP dampens TNF-α gene expression in
LPS-stimulated microglia via Nur77-mediated impair-
ment of p65 phosphorylation and acetylation and an
epigenetic regulation mechanism. Moreover, blockade of
PI3K/Akt/mTOR signaling-mediated translation of
TNF-α mRNA is also involved in 6-MP’s inhibitory
actions. Because downregulation of microglia-mediated
inflammation may offer prospective clinical therapeutic
benefits for neuroinflammation-related neurodegenera-
tive disorders, the findings presented here may provide
new insight into the clinical applications of this old drug
in targeting various neurodegenerative diseases.
Additional files
Additional file 1: Figure S1. LPS-induced activation of PKA and MSK1
are not suppressed by 6-MP. BV-2 cells were stimulated with 100 ng/ml
LPS for the indicated times with or without 16 h pretreatment with 6-MP
(50 μM). Immunoblots were set up to detect phosphorylated VASP
(Ser157) and MSK1 (Ser376). Images are representative of three
independent experiments. (TIF 400 kb)
Additional file 2: Figure S2. 6-MP does not increase Nurr1 or NOR-1
protein levels in BV-2 cells. Cells were treated with various concentrations
of 6-MP for 1 h (mRNA) or 16 h (protein). Nurr1 (a) and NOR-1 (b)
transcripts and proteins were analyzed using real-time RT-PCR or
Western blotting, respectively. (TIF 332 kb)
Additional file 3: Figure S3. Physical interaction between Nur77 and
p65. BV-2 cells were pretreated with 6-MP (50 μM) for 16 h followed by
exposure to LPS (100 ng/ml) for 60 min. Nuclear extracts were harvested
for immunoprecipitation (IP) experiments using anti-Nur77 and anti-p65
antibodies. Immunoblot (IB) analyses of the immunoprecipitates were
performed using these antibodies. The immunoblots are representative
of three independent experiments. (TIF 280 kb)
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